Objective: Considering inconsistent findings and the absence of published longitudinal studies on large-scale community cohorts, this study aims to assess the relationship between treatment modalities (injectable vs. oral therapy) and psychiatric symptoms and QOL in individuals with multiple sclerosis. Method: This cross-sectional study involved multiple sclerosis 42 patients diagnosed per McDonald's 2017 criteria. Participants were grouped into those receiving injectable disease-modifying therapies (DMTs) (19 patients), oral DMTs (22 patients), and healthy controls (20 patients). Expanded Disability Status Scale (EDSS), Hamilton Depression Rating Scale (HAM-D), 36-item Short Form Survey (SF-36), Hamilton Anxiety Rating Scale (HAM-A), and Headache Impact Test were applied. Results: The healthy control group exhibited statistically higher sf-36 total scores than the oral and injectable therapy groups (p
Key words: Depression, Anxiety, Multiple Sclerosis, Oral Therapy, Injectable Therapy.
|
